130 filings
6-K
NBTX
Nanobiotix
6 Mar 24
Nanobiotix to Present at Upcoming Investor Conferences in March
4:15pm
6-K
NBTX
Nanobiotix
13 Feb 24
Voting Rights and Shares Capital of the Company
4:15pm
6-K
NBTX
Nanobiotix
31 Jan 24
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
4:15pm
6-K
NBTX
Nanobiotix
29 Jan 24
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
4:15pm
6-K
NBTX
Nanobiotix
11 Jan 24
Voting Rights and Shares Capital of the Company
5:50pm
6-K
sk460tgw 3j9mse9ld
26 Dec 23
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
6:05am
6-K
b0huztbrfymhxh4lincz
13 Dec 23
Voting Rights and Shares Capital of the Company
4:15pm
6-K
tsjseyj7qy5
4 Dec 23
Current report (foreign)
4:32pm
6-K
fjtl mm8h
13 Nov 23
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
4:15pm
6-K
l5ana eb4fb
9 Nov 23
Current report (foreign)
4:15pm
6-K
bbrw4dibj5608rmhzfvk
9 Nov 23
Voting Rights and Shares Capital of the Company
9:00am
6-K
jgv17nol0ymypycq0w
8 Nov 23
NANOBIOTIX Announces Closing of Global Offering
7:53am
6-K
vj2p8496f ex
7 Nov 23
Current report (foreign)
7:02am
6-K
k1zwi5 pa
2 Nov 23
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
10:56am
6-K
ljt6i
1 Nov 23
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
6:36pm
6-K
wp225
23 Oct 23
Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data
6:00am
6-K
3lpnnu f9hnfaz5ck2
11 Oct 23
Voting Rights and Shares Capital of the Company
5:24pm
6-K
sdbcuhe6vtyv8eiw38ue
4 Oct 23
Current report (foreign)
4:43pm
6-K
kudbctlt4s9fgpv
29 Sep 23
Current report (foreign)
4:15pm
6-K
1detmxl2mp46 a5cybhb
28 Sep 23
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
4:15pm